Comparative Pharmacology
Head-to-head clinical analysis: EMTRIVA versus LAMIVUDINE ZIDOVUDINE 150 MG 300 MG TABLETS CO PACKAGED WITH NEVIRAPINE 200 MG TABLETS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRIVA versus LAMIVUDINE ZIDOVUDINE 150 MG 300 MG TABLETS CO PACKAGED WITH NEVIRAPINE 200 MG TABLETS.
EMTRIVA vs Lamivudine/Zidovudine 150 mg/300 mg Tablets Co-packaged with Nevirapine 200 mg Tablets
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
Lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV-1 reverse transcriptase by competitive inhibition and chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase and blocks RNA-dependent and DNA-dependent DNA polymerase activities.
Emtricitabine 200 mg orally once daily.
One tablet (lamivudine 150 mg/zidovudine 300 mg) orally twice daily, plus one tablet (nevirapine 200 mg) orally once daily for first 14 days, then one tablet (nevirapine 200 mg) orally twice daily thereafter.
None Documented
None Documented
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Lamivudine: terminal half-life 5-7 hours in adults; prolonged in renal impairment. Zidovudine: terminal half-life 1.1-1.3 hours; prolonged to 1.7 hours in renal impairment. Nevirapine: terminal half-life 45 hours (single dose), reducing to 25-30 hours after multiple dosing due to autoinduction.
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Lamivudine: primarily renal excretion of unchanged drug (approximately 70% within 24 hours) via glomerular filtration and active tubular secretion. Zidovudine: renal excretion (approximately 14% unchanged) and hepatic metabolism to GAZT (glucuronide), with 74% of dose recovered in urine as total zidovudine and metabolites. Nevirapine: 81% of dose recovered in urine (primarily metabolites) and 10% in feces; <5% excreted unchanged in urine.
Category C
Category A/B
Antiretroviral, NRTI
NRTI